An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel
Abstract Allergic rhinitis is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom co...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-01-01
|
Series: | npj Primary Care Respiratory Medicine |
Online Access: | https://doi.org/10.1038/s41533-016-0001-y |
id |
doaj-6ff24193c29741bfb36b50aedfe7c9c0 |
---|---|
record_format |
Article |
spelling |
doaj-6ff24193c29741bfb36b50aedfe7c9c02020-12-07T23:54:11ZengNature Publishing Groupnpj Primary Care Respiratory Medicine2055-10102017-01-012711810.1038/s41533-016-0001-yAn algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panelBrian Lipworth0Jon Newton1Bhaskar Ram2Iain Small3Jürgen Schwarze4Ninewells Hospital and Medical School, Scottish Centre for Respiratory ResearchForth Valley Royal Hospital, Forth Valley Health BoardAberdeen Royal Infirmary, Grampian Health BoardPeterhead Surgery, Grampian Health BoardChild Life and Health, The University of EdinburghAbstract Allergic rhinitis is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom control is pivotal to successful allergic rhinitis management, and relies mostly on pharmacotherapy. While it is recognised that most mild-moderate allergic rhinitis symptoms can be managed successfully in primary care, important gaps in general practitioner training in relation to allergic rhinitis have been identified. With the availability of new effective combination therapies, such as the novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in a single device (Dymista®; Meda), the majority of allergic rhinitis symptoms can be treated in the primary care setting. The primary objective of this consensus statement is to improve diagnosis and treatment of allergic rhinitis in primary care, and offer guidance on appropriate referral of difficult-to-treat patients into secondary care. The guidance provided herein outlines a sequential treatment pathway for allergic rhinitis in primary care that incorporates a considered approach to improve the management of allergic rhinitis symptoms and improve compliance and patient satisfaction with therapy. Adherence with this care pathway has the potential to limit the cost of providing effective allergic rhinitis management in the UK by avoiding unnecessary treatments and investigations, and avoiding the need for costly referrals to secondary care in the majority of allergic rhinitis cases. The fundamentals presented in this consensus article should apply in most health-care settings.https://doi.org/10.1038/s41533-016-0001-y |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Brian Lipworth Jon Newton Bhaskar Ram Iain Small Jürgen Schwarze |
spellingShingle |
Brian Lipworth Jon Newton Bhaskar Ram Iain Small Jürgen Schwarze An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel npj Primary Care Respiratory Medicine |
author_facet |
Brian Lipworth Jon Newton Bhaskar Ram Iain Small Jürgen Schwarze |
author_sort |
Brian Lipworth |
title |
An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel |
title_short |
An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel |
title_full |
An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel |
title_fullStr |
An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel |
title_full_unstemmed |
An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel |
title_sort |
algorithm recommendation for the pharmacological management of allergic rhinitis in the uk: a consensus statement from an expert panel |
publisher |
Nature Publishing Group |
series |
npj Primary Care Respiratory Medicine |
issn |
2055-1010 |
publishDate |
2017-01-01 |
description |
Abstract Allergic rhinitis is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom control is pivotal to successful allergic rhinitis management, and relies mostly on pharmacotherapy. While it is recognised that most mild-moderate allergic rhinitis symptoms can be managed successfully in primary care, important gaps in general practitioner training in relation to allergic rhinitis have been identified. With the availability of new effective combination therapies, such as the novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in a single device (Dymista®; Meda), the majority of allergic rhinitis symptoms can be treated in the primary care setting. The primary objective of this consensus statement is to improve diagnosis and treatment of allergic rhinitis in primary care, and offer guidance on appropriate referral of difficult-to-treat patients into secondary care. The guidance provided herein outlines a sequential treatment pathway for allergic rhinitis in primary care that incorporates a considered approach to improve the management of allergic rhinitis symptoms and improve compliance and patient satisfaction with therapy. Adherence with this care pathway has the potential to limit the cost of providing effective allergic rhinitis management in the UK by avoiding unnecessary treatments and investigations, and avoiding the need for costly referrals to secondary care in the majority of allergic rhinitis cases. The fundamentals presented in this consensus article should apply in most health-care settings. |
url |
https://doi.org/10.1038/s41533-016-0001-y |
work_keys_str_mv |
AT brianlipworth analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel AT jonnewton analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel AT bhaskarram analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel AT iainsmall analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel AT jurgenschwarze analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel AT brianlipworth algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel AT jonnewton algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel AT bhaskarram algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel AT iainsmall algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel AT jurgenschwarze algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel |
_version_ |
1724397041136697344 |